Acceleron Pharma to Present at the MBC’s MASS Opportunities Conference
CAMBRIDGE, MA – October 30, 2006 – Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, today announced that Glenn Batchelder, Chief Executive Officer, will provide a corporate presentation at the Massachusetts Biotechnology Council’s MASS Opportunities Conference on Thursday, November 2, 2006 at 11:10 a.m. (EST). The conference will be held at the Hilton Logan Airport Hotel, Boston, MA.
About Acceleron Pharma
Acceleron is a privately held biopharmaceutical company focused on developing and commercializing regenerative therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases. The company’s scientific platform is based on its unique approach to harness the clinical potential of naturally-occurring tissue growth factors to treat diseases with significant unmet medical need. The company’s lead program is an anabolic bone agent being developed to reverse bone loss in diseases such as osteoporosis and cancer. Additionally, the company has therapeutic programs in the areas of muscle growth, angiogenesis and metabolic diseases. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock Associates.
Contact: Steven Ertel, Vice President Business Development, Acceleron Pharma, tel: 617-576-2220 x234 and Paul Kidwell (Media) Kidwell PR, tel: 617-296-3854